Every woman. Well Revenue and Competitors

London, UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Every woman. Well's estimated annual revenue is currently $3.8M per year.(i)
  • Every woman. Well's estimated revenue per employee is $201,000

Employee Data

  • Every woman. Well has 19 Employees.(i)
  • Every woman. Well grew their employee count by -14% last year.

Every woman. Well's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Medical and Development Officer and Co-founderReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Programme ManagerReveal Email/Phone
6
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.9M2936%N/AN/A
#2
$21.1M1055%N/AN/A
#3
$113.4M5641%N/AN/A
#4
$20.9M104-5%N/AN/A
#5
$37M1849%N/AN/A
#6
$45.4M226-24%N/AN/A
#7
$16.1MN/AN/AN/A
#8
$69.7M3470%N/AN/A
#9
$8M403%N/AN/A
#10
$25.5M12728%N/AN/A
Add Company

What Is Every woman. Well?

Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones. Viramal's patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal's products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company's products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy. The portfolio is made up of products in the following area's: 1. Sex Steroid Hormone Deficiencies * Testosterone Replacement for Men * Menopausal Hormone Therapy 2. Reproductive & Fertility * Fertility Support * Endometriosis & Fibromyomas – treating symptoms and enabling fertility within women of reproductive age 3. Contraception & General Sexual Health * Safer and more patient-acceptable daily & emergency contraceptives * Gynaecological health Viramal's lead product, TestoCream, is expected to be filed for a New Drug Application to the FDA in the US in 2017/18. TestoCream is a testosterone replacement therapy, similar to a cosmetic cream, applied to the skin. Unlike competing products, TestoCream is neither messy nor watery, requiring a smaller area for application, and it is also quick drying. Testosterone is only soluble in alcohol, with competing products having an alcohol content of around 70% or more. TestoCream offers a far safer alternative, having less than 3.5% alcohol, reducing the risk of skin irritation.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$3.8M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Every woman. Well News

2022-04-20 - A woman charged with illegal voter registration won't be prosecuted ...

Moses' previous felony convictions permanently barred her from voting. In 2015, she pleaded guilty to two felonies as well as three misdemeanors...

2022-04-20 - How 'The Primacy of Five' depicts every woman in our world

The exhibition features 13 canvases that include portraits, as well as three other paintings in a half-finished stage done from life,...

2022-04-17 - Texas' Planned Execution of Melissa Lucio Raises Questions

Texas Is About to Execute a Woman for Her Daughter's Death. But She May Well Be Innocent. melissa-lucio-confession-...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M19-54%$18.6M
#2
$2.7M19-41%N/A
#3
$2.3M19-27%N/A
#4
$2.3M19-17%N/A
#5
$2.5M1927%N/A